Drugs / RPX2014
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02073812 | Feb → Apr 2014 | — | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Completed | No outcome recorded |
| Phase 1 | NCT02020434 | Jan → Sep 2014 | — | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Completed | No outcome recorded |
| Phase 1 | NCT01897779 | Jul 2013 → Feb 2014 | bacterial infectious disease | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPX2014 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02073812 ↗ |
| Modality | Small molecule | “a carbapenem (RPX2014)” NCT02020434 ↗ |
| Route | Intravenous | “intravenous RPX2014 and RPX7009” NCT01897779 ↗ |